Management strategy for adverse events of immune checkpoint inhibitors

VernacularTitle:免疫检查点抑制剂治疗肿瘤的不良反应及管理策略
Author: Shimin ZHANG ^{1
,

2} ; Yuan CHEN ; Qian CHU
Author Information

1. 华中科技大学同济医学院附属同济医院肿瘤中心武汉市430000
2. 泰康同济(武汉)医院
Keywords: immune checkpoint inhibitors; adverse events; treatment principles
From: Chinese Journal of Clinical Oncology 2018;45(12):609-613
CountryChina
Language:Chinese
Abstract: Currently, immune checkpoint inhibitors (ICPIs) are the most compelling approach in cancer therapy, which expanded the boundary of treatment of cancer to immune-based therapy. Compared to traditional chemotherapy, immunotherapy significantly pro-longs survival while conferring fewer side effects. Because of the new mechanism of the ICPIs with good clinical efficacy, they have been approved for sale in a short time. However, the mechanism of immune-related adverse events have yet fully understood for a standardized management strategy. With further development of immunotherapy and possible combination therapy, adverse events of ICPIs gain more attention. Here, we focuses on the reported adverse events and the treatment experience to provide theoretical ba-sis for their treatment.